Advances in cell signaling research using 3' RNA-seq

Unraveling the complexity of cell signaling pathways can advance the understanding of various diseases. The use of 3’ RNA sequencing has been instrumental in this field, creating a need for high-throughput solutions that afford increased accuracy, specificity and sensitivity. QIAGEN's QIAseq UPX 3' Transcriptome Kit, also available as a service, addresses these requirements by providing high-throughput 3' transcriptome NGS from ultralow amounts of RNA.

Discover through inspirational stories below how QIAseq UPX 3' Transcriptome technology facilitated a deeper understanding of diabetes through gene expression and cell signaling analysis and interpretation.

Simona Chera , Ph.D.,
Associate Professor,
University of Bergen

“For us, the QIAseq UPX 3’ Transcriptome approach was a life-saver, allowing high- throughput sequencing on ultralow amounts of RNA isolated from hard-to-process samples. The pilot results obtained with QIAGEN Genomic Services exceeded our expectations. In my opinion, this is certainly an approach to keep in mind when the RNA quantity is below the minimal threshold.”

Encapsulation boosts islet-cell signature in differentiating human hiPSCs via integrin signaling

Recent compelling research by Dr. Simona Chera and her team at the Department of Clinical Science, University of Bergen, who investigated the development of human-induced pluripotent stem cells (hiPSCs) into insulin-producing pancreatic islet cells for potential use in diabetes treatment. Discover how QIAseq UPX 3' Transcriptome Kits, as well as GeneGlobe and QIAGEN Digital Insights played a fundamental role in accelerating sequencing and data analysis for this study.

Read the Nature publication

Matthew Dodson, Ph.D.,
Post-Doctoral Researcher,
University of Arizona

"QIAGEN's UPX 3’ Transcriptome service allowed us to generate a large-scale RNA-seq data set that facilitated our discovery of key gene expression changes that drive our disease model."

Uncovering the connection between arsenic and type II diabetes

Exciting new research by Dr. Matthew Dodson and Dr. Donna Zhang from the University of Arizona, who investigated the role of Nrf2 regulation in diabetic disease. Learn how QIAseq UPX 3' Transcriptome technology – as part of QIAGEN's Genomic Services – played a crucial role in establishing a connection between environmental arsenic exposure and type II diabetes.

Read the story

On-demand webinar – watch now

Investigating the Nrf2 transcriptome as a driver of arsenic-promoted type II diabetes

Speakers: Matthew Dodson, Ph.D., Department of Pharmacology and Toxicology, University of Arizona and Raphael Werding, M.Sc., Genomic Services, QIAGEN

Responsive image
Responsive image

Get started with QIAseq UPX 3’ technology

Boost your gene expression and pathway research – request your QIAseq UPX 3' Transcriptome Trial Kit or reach out to QIAGEN Genomic Services to discuss your project.

Thank you for contacting us. We will be in touch with you shortly.

Want to discuss your RNA-seq sample types and sequencing project with our RNA-seq Specialist Team? Get in touch with us by completing the form below.

Dummy field DO NOT USE Need to be hidden in CSS on LP
If Opp Type is INSTRUMENT // For SP creation / could be hidden field
If Opp Type is INSTRUMENT // For SP creation / could be hidden field
For SP creation / could be hidden field
For SP creation / could be hidden field
For SP creation / could be hidden field
For SP creation / could be hidden field
For SP creation / could be hidden field
For SP creation / could be hidden field
For SP creation / could be hidden field
For SP creation / could be hidden field
For SP creation / could be hidden field
Required only for USA & Canada
I hereby give QIAGEN the consent to contact me via email and phone (subject to the contact information provided above) with further special offers, contests and product information.

* Required field

† By checking the box above, you submit your information to QIAGEN, who will use it to communicate with you regarding this topic. QIAGEN may also use your personal information for internal business and marketing purposes, including but not limited to webinar and raffle registration, product, trial, educational and events information. The information will not be sold to any third party. QIAGEN may transfer your personal information to our CRM system (hosted by SalesForce.com, Inc. and Oracle Corp.) and our commercial partners solely for the purposes of data hosting, phone calls and QIAGEN email distribution. You may unsubscribe at any time. If you withdraw your consent we will not be able to communicate with you on this topic. Your data will be processed in compliance with applicable privacy laws including the EU General Data Protection Regulation. For further details please refer to our Privacy Policy.